Moderna, Merck mRNA cancer vaccine met key melanoma endpoints, detailed data show
Full data from the Merck-Moderna mRNA-4157 melanoma trial confirmed the vaccine cut recurrence or death risk, a key validation for mRNA cancer therapy.
STAT · +14 outlets
Trump delivers Oval Office announcement on weight-loss drug costs
The pricing announcement is projected to save $64.3B over 10 years and follows a broad push to lower GLP-1 costs for US patients.
BusinessWorld Online · +12 outlets
Aardvark Therapeutics shares swing as FDA lifts ARD-101 hold, HERO/OLE data reviewed
The FDA lifted its clinical hold on Aardvark's ARD-101 for Prader-Willi syndrome, but mixed exploratory Phase 3 HERO data and mounting class actions left the st
The Manila Times · +9 outlets
AstraZeneca wins FDA accelerated approval for Ultomiris in IgA nephropathy
Ultomiris becomes a new treatment option for adults with primary IgA nephropathy, expanding AstraZeneca's rare disease franchise.
Pharmaceutical Executive · +14 outlets
Pfizer halts development of closely watched weight-loss drug
Pfizer's decision to stop work on an obesity candidate adds to questions about its ability to compete in the crowded GLP-1 market.
BusinessWorld Online · +7 outlets
Teva introduces first generic GLP-1 for weight loss as price war intensifies
A generic entrant into the GLP-1 market signals the start of price competition among weight-loss drugs.
BusinessWorld Online · +1 outlets
GLP-1 boom in India, China, Brazil could create $22B market, JPMorgan says
Emerging-market demand for obesity drugs is projected to add billions in new sales as access expands beyond the US and Europe.
Business Standard · +2 outlets
Biohaven shares surge as FDA accepts Vyglyxia resubmission, approves Vyglxia
Biohaven's stock posted its biggest single-day gain in years after the FDA accepted and approved its Vyglxia filing.
Seeking Alpha · +3 outlets
Roche 9M 2026 sales rise on strong drug demand, pipeline advances
Roche's nine-month results showed its top five medicines generating CHF 16.8B in sales, up 12% excluding currency effects.
TradingView · +8 outlets
Korea's first homegrown GLP-1 obesity drug Eppe set for Oct. 29 launch
Hanmi's Eppe will become Korea's first domestically developed GLP-1 obesity drug when it reaches patients this month.
Korea JoongAng Daily · +3 outlets
Roche adds Hanmi obesity drug HM17321 to pipeline via Genentech
Roche formally added Hanmi's HM17321 obesity candidate to its pipeline, deepening the pharma's metabolic disease push.
Chosunbiz · +14 outlets
Hanmi Pharmaceutical's next-generation obesity drug named Zantrutide by WHO
The WHO international nonproprietary name for Hanmi's HM15275 marks a regulatory milestone for the Korean obesity candidate.
Seoul Economic Daily · +2 outlets
MDMA-assisted therapy could get FDA approval as soon as January, advocate says
An advocate says MDMA-assisted therapy for PTSD could secure FDA approval early next year, a closely watched psychedelic regulatory decision.
New York Post · +14 outlets
23andMe pivots from drug discovery to GLP-1 weight loss prescriptions
The consumer genetics company is shifting its business model toward telehealth prescribing of weight-loss drugs.
BusinessWorld Online · +2 outlets
Arbutus Biopharma says FDA lifts clinical hold on AB-101 hepatitis B drug
The FDA removed its hold on Arbutus' experimental oral hepatitis B drug, allowing the company to resume development.
Mugglehead Investment Magazine · +9 outlets
GLP-1 compounder issues recall for copycat Zepbound
A compounding pharmacy recalled its copy of Zepbound, highlighting safety concerns around compounded GLP-1s.
BioPharma Dive · +3 outlets
Tango moves pancreatic cancer drug to Phase 3 despite sinking response rates
Tango Therapeutics will advance its pancreatic cancer candidate to Phase 3 even as ESMO 2026 data showed declining response rates.
BioSpace · +1 outlets
Mark Cuban's Cost Plus Drugs teams with Humana on employer drug costs
The partnership aims to lower prescription costs for employers, adding to pressure on traditional pharmacy benefit models.
Medical Economics · +1 outlets